Author: admin

Please chooseI’m not a medical professional.Allergy and ImmunologyAnatomyAnesthesiologyBiostatisticsCardiac/Thoracic/Vascular SurgeryCardiologyCritical CareDentistryDermatologyDiabetes and EndocrinologyEmergency MedicineEpidemiology and Public HealthFamily MedicineForensic MedicineGastroenterologyGeneral PracticeGeneticsGeriatricsHealth PolicyHematologyHIV/AIDSHospital-based MedicineI’m not a medical professional.Infectious DiseaseIntegrative/Complementary MedicineInternal MedicineInternal Medicine-PediatricsMedical Education and SimulationMedical PhysicsMedical StudentNephrologyNeurological SurgeryNeurologyNuclear MedicineNutritionObstetrics and GynecologyOccupational HealthOncologyOphthalmologyOptometryOral MedicineOrthopaedicsOsteopathic MedicineOtolaryngologyPain ManagementPalliative CarePathologyPediatricsPediatric SurgeryPharmacologyPhysical Medicine and RehabilitationPlastic SurgeryPodiatryPreventive MedicinePsychiatryPsychologyPulmonologyRadiation OncologyRadiologyRheumatologySubstance Use and AddictionSurgeryTherapeuticsTraumaUrologyMiscellaneous

Nexxen International (NasdaqGM:NEXN) has seen a wave of attention after it lowered its full-year 2025 financial guidance. The move follows Q3 results that landed in line with expectations but showed some mixed signals.

See our latest analysis for Nexxen International.

The lowered financial guidance and cautious analyst commentary have certainly weighed on Nexxen International’s momentum. The share price has slipped by 27.3% over the past month and 40.5% year-to-date. While the stock has faced near-term pressure, its five-year total shareholder return still stands strong at over 78%, suggesting that longer-term holders have fared much better than recent buyers.

If you want to see what other companies are catching investors’ attention amid shifting forecasts, now is a perfect time to check out fast growing stocks with high insider ownership.

So after a sharp drop in shares and new analyst targets below previous highs, does Nexxen International now trade at a compelling discount? Or is the market already reflecting slower growth in its current price?

Nexxen International’s last close at $6.43 is well below the most widely followed fair value estimate of $16.14. This raises questions about what’s behind such a significant gap in expectations.

The expanded, long-term partnership with VIDAA secures exclusive access to valuable CTV inventory and ACR data. This enables Nexxen to uniquely monetize North American and international connected TV audiences as VIDAA grows its global footprint, which could drive higher revenues and a larger addressable market starting in 2026.

Read the complete narrative.

Curious why a digital advertising company would warrant such a premium? The narrative focuses on ambitious growth assumptions and aggressive future profit multiples. Something in Nexxen’s financial trajectory may surprise you. Ready to discover what’s fueling this major valuation call?

Result: Fair Value of $16.14 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, weaker-than-expected CTV revenue growth and rising data privacy regulations remain notable risks that could challenge bullish expectations in the future.

Find out about the key risks to this Nexxen International narrative.

If the current story doesn’t fit your view, or you want to dive in yourself, you can shape your own analysis in just a few minutes. So why not Do it your way?

A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Nexxen International.

If you want every chance at finding your next big winner, don’t wait on the sidelines. Use the Screener to spot where momentum is building now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NEXN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com